30 mars 2026 Sweden
Maria Karlsson Osipova - analyst at DNB Carnegie, interviews Diamyd Medical CEO Ulf Hannelius and board member Mark Atkinson, and Joshua Vieth, BreakthroughT1D, following the DIAGNODE-3 interim readout.
|
30 mars 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius and board member, Professor Mark Atkinson, comment on the negative interim readout from the ongoing Phase 3 study DIAGNODE-3, announced on March 27, 2026. Read the article here
|
30 mars 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius and board member, Professor Mark Atkinson, comment on the interim readout from the Phase 3 study.
Produced in collaboration with Direkt Studios and moderated by Christian Ploog.
|
26 mars 2026 Sweden
In an article, BioStock highlights Diamyd Medical as a company attracting investor interest ahead of its upcoming Phase III data readout. Read the article here
|
25 mars 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius and CFO Niklas Axelsson present the company’s quarterly report and provide an update on the current status of the business.
The report was published on March 25, 2026. Produced in collaboration with BioStock, moderated by Cecilia Hallström.
|